SCOPE TODAYS SESSION. Case 1: Case 2. Basic Theory Stuff: Heavy Stuff. Basic Questions. Basic Questions

Similar documents
Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14

GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD

Carcinoid Tumors: The Beginning and End. Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011

Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors

NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction

Community Case. Saeed Awan R5

Management of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms

Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide)

Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC

Surgical Therapy of GEP-NET: An Overview

PNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.

NET und NEC. Endoscopic and oncologic therapy

WHO e TNM: Importanza della classificazione nell approccio terapeutico

Neuroendocrine Tumors

Tumor markers. Chromogranin A. Analyte Information

Objectives. Terminology 03/11/2013. Pitfalls in the diagnosis of Gastroenteropancreatic Neuroendocrine Tumors. Pathology Update 2013

Guide for patients, carers and doctors about Neuroendocrine (NET) Cancer

An Overview of NETS. Richard R.P. Warner M.D

Small cell neuroendocrine carcinoma icd 10

ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID

Appendix 4: WHO Classification of Tumours of the pancreas 17

Disclosure of Relevant Financial Relationships

Lu 177-Dotatate (Lutathera) Therapy Information

Rare GI Malignancies

ADRENAL MEDULLARY DISORDERS: PHAEOCHROMOCYTOMAS AND MORE

Neuroendocrine Tumours (NETs) - Treatment Pathway Toolkit. See inside for further information on rarer types of NETs

Pathology testing and Neuroendocrine tumours (NETs)

Fig. 59 Malignant phaeochromocytoma, hepatic metastasis.

3/23/2017. Differentiation: Differentiation: Immunohistochemistry. Well Differentiated vs. Poorly Differentiated Neuroendocrine Neoplasms

Surgery for complications of advanced mid-gut carcinoid may be associated with prolonged survival: report of two cases

Rare Neuroendocrine Tumours and Cancers of Endocrine Organs

MEDICAL MANAGEMENT OF METASTATIC GEP-NET

NET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Case Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors

Radiology Pathology Conference

Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging

What s New for 8 th Edition

Prior Authorization Review Panel MCO Policy Submission

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Afternoon Session Cases

Type 2 gastric neuroendocrine tumor: report of one case

Index. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type.

RECURRENT ADRENAL DISEASE. Megan Applewhite Endorama 2/19/2015 SR , SC

Oncology 101. Cancer Basics

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

Gastric and Oesophageal Neuroendocrine tumours. Dr Tim Bracey, Consultant Pathologist MBChB PhD MRCS FRCPath

GOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles

GOBLET CELL CARCINOID

Neuroendocrine Carcinoma. Lebanon Neuroendocrine Neoplasms of H&N Nov /7/2011. Broad Classification:

Review of Gastrointestinal Carcinoid Tumors: Latest Therapies

NEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS

THE HIGHS AND LOWS OF ADRENAL GLAND PATHOLOGY

Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010

Hepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization

Goblet Cell Carcinoids of the Appendix

CEA (CARCINOEMBRYONIC ANTIGEN)

Differentiation of Appendiceal Carcinoids By Marker Gene Expression

Imaging of Neuroendocrine Metastases

Index. Note: Page numbers of article titles are in boldface type.

Neuroendocrine tumors of GI and Pancreatobiliary tracts. N. Volkan Adsay, MD

G3.02 The malignant potential of the neoplasm should be recorded. CG3.02a

Renal Parenchymal Neoplasms

Pediatric Retroperitoneal Masses Radiologic-Pathologic Correlation

Diagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD. November 18, 2017

When Immunostains Can Get You Into Trouble (and how they can help you out): Neuroendocrine Neoplasms

Surgical Management of Neuroendocrine Tumors of the Gut. Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School

COLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING

CRITICAL ANALYSIS OF NEN GUIDELINES. G Pentheroudakis Associate Professsor of Oncology Medical School, University of Ioannina Chair, ESMO Guidelines

Endocrine and Hereditary Considerations in Neuroendocrine Tumors

Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 Final Pathology:

Neuroendocrine neoplasms of the lung

Learning. A part of your guide to Neuroendocrine Tumours (NETs)

Management of Neuroendocrine Tumors

Colon and Rectum: 2018 Solid Tumor Rules

Case Report Neuroendocrine Cancer of Rectum Metastasizing to Ovary

Fast, automated, precise

Grade 2 Ileum NET with liver and bone metastasis

NET / GIST / MEN. 2014/2015 FCDS Educational Webcast Series. October 16, Steven Peace, CTR

Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.

Somatuline Depot. Somatuline Depot (lanreotide) Description

objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University

THE FACTS YOU NEED TO KNOW

Cross-sectional Imaging of Neuroendocrine Tumors of the Gastrointestinal Tract

Patient Information. Age: 8 y/o Sex: Female. Date of Admission: Date of Discharge:

Right Iliac Fossa Pain

OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS

Neuroendocrine Tumors

Treatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece

Survivorship care of Neuroendocrine Tumours(NETs) from a Specialised Nursing Perspective

Sex: 女 Age: 51 Occupation: 無 Admission date:92/07/22

Pancreas Case Scenario #1

Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)

Lung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.

SUPPLEMENTARY INFORMATION

Neuroendocrine Tumor of Unknown Primary Accompanied with Stomach Adenocarcinoma

Transcription:

MONDAY TEACHING

SCOPE TODAYS SESSION Case 1: Basic Questions Case 2 Basic Questions Basic Theory Stuff: AJCC TNM + Stage Group for Carcinoid of the Appendix Management of Carcinoid of the Appendix (NCCN) Heavy Stuff Neuroendocrine Tumours Carcinoid Tumours

CASE 1 19yo male HPI: 24Hr central abdominal pain Radiates RIF Nausea, 1 x vomit Anorexia Examination RR21 Temp 38.1 HR 91 Tender RIF Guarded RIF Scrotum normal PMH Well, no allergies, no meds, vaccinated Bloods: WCC 14 No significant family Hx

CASE 1 What is the Diagnosis? Does this patient have SIRS? Do you image this patient? If so how? At surgery you find this: Describe.. How can carcinoid of the appendix present?

BASIC QUESTIONS What is the incidence of incidental carcinoid at appendicectomy? Which histologic type should we be most concerned about, and what is special about their recommended treatment? We will discuss management later

CASE 2 HPI: Worse pain(10/10), D+V for 3 days Nil fevers or chills, nil infectious contact Flushing of face recently PMH: Colonscopy 12 months ago? Normal Cramping RIF pain /12 Diarrhoea AF, IHD, T2DM Examination: Afebrile HR 100 irregular Dry mucous membranes Flushed cheeks Abdomen: soft, tender epigastrium and RIF, nil rebound tenderness or guarding Pigmented lower legs Bloods; WCC: 18.5, CRP: 109

CASE 2 Basic Questions: What is the possible diagnosis? Do you want imaging? Do you want any other tests?

ABDOMINAL X-RAY Describe this image?

FURTHER IMAGING DESCRIBE THESE IMAGES?

THE TYPICAL CT DESCRIPTION CARCINOID TUMOUR: mass with soft-tissue attenuation spiculated borders and radiating surrounding strands. Calcification may be noted in the tumor. Linear strands within the mesenteric fat probably are thickened and retracted vascular bundles and represent peritumoral desmoplastic reaction. Lymphadenopathy and liver metastases may be visualized on CT scans

WHY DOES THIS PATIENT HAVE THE ADDITIONAL FINDINGS? pellagra

Basic Theory Stuff Appendiceal Carcinoid Most common tumour of the appendix Found in 0.5%- 1% of appendicectomy specimens Accounts for 85% of all appendiceal tumours Usually an incidental finding found during appendicectomy Appencideal Location: 75% occur at the tip, 15% in the middle and 10% at the base of the appendix Size: 80% < 1 cm, 5% >2 cm in diameter

AJCC 7 th Ed Appendiceal Carcinoid Appendix Classification New to 7 th Edition Carcinomas (i.e. adenocarcinoma) Carcinoid (this is separate to SB and NET) Although neuroendocrine in nature they are seperately classified because of greater frequency, variety of subtypes and behavioural differences to other gastrointestinal NET T: T0 T1 <2cm T2 2-4cm or extends caecum T3 >2cm or extends ileum T4 invades other organs N: N0 N1 = regional nodes M M0 M1 other organ Stages: I-II = T1-3 III = N1 IV = M1 Note: Goblet cell carcinoid staged as carcinoma

MANAGEMENT APPENDICEAL CARCINOID (NCCN)

METASTATIC DISEASE

HEAVY DUTY STUFF THE HISTORY Characterized in 1907 by Siegfried Oberndorfer, a German pathologist. karzinoide, or "carcinoma-like", to describe the unique feature of behaving like a benign tumor despite having a malignant appearance microscopically. Endocrine-related properties were later described by Gosset and Masson in 1914, and these tumors are now known to arise from the enterochromaffin (EC) and enterochromaffin-like (ECL) cells of the gut. In 2000, the World Health Organization redefined "carcinoid", but this new definition has not been accepted by all practitioners. The 2000 WHO definition states:[5] Neuroendocrine tumors: Neuroendocrine tumors are growths that look benign but that might possibly be able to spread to other parts of the body. Neuroendocrine cancers Neuroendocrine cancers are abnormal growths of neuroendocrine cells which can spread to other parts of the body.

NETS Classfication / Nomenclature Battlefield: NANETS ENETS WHO AJCC But: Neuroendocrine Tumours are neoplasms of neuroendocrine cells. They can occur in the lungs, GIT system, ovaries, adrenals, kidneys etc. They are divided into functional (forming a clinical syndrome) and non-functional. Commonly arise in Kulchitsky cells or similar enterochromaffin-like cells.

NET GENETIC ASSOCIATIONS multiple endocrine neoplasia type 1 (MEN1) multiple endocrine neoplasia type 2 (MEN2) von Hippel-Lindau (VHL) disease neurofibromatosis type 1 tuberous sclerosis Carney complex

NEUROENDOCRINE TUMOURS (NETS) NETS By Anatomical Site: Pituitary gland: Neuroendocrine tumor of the anterior pituitary Thyroid gland: - medullary carcinoma Parathyroid tumors Thymus and mediastinal carcinoid tumors Pulmonary neuroendocrine tumors Bronchus Pulmonary carcinoid tumors Small-cell lung cancer (SCLC) LCNEC\ Extrapulmonary small cell carcinomas (ESCC or EPSCC) Gastroenteropancreatic neuroendocrine tumors (GEP-NET) Carcinod: Foregut GEP-NET Midgut GEP-NET Hindgut GEP-NET Pancreatic endocrine tumors (pnet) Adrenal tumor: Pheochromocytoma Peripheral nervous system tumors, such as: Schwannoma paraganglioma Neuroblastoma Merkel cell carcinoma of skin

CARCINOID TUMOURS (GEP-NET) BY SITE

INVESTIGATIONS FOR CARCINOID TUMOURS 24 hour urine collection 5HIAA Chromogranin A Imaging: CT Chest/Abdomen/Pelvis Octreotide scan Dotatate PET scan MIBG Scopes: Bronchoscopy Gastroscopy Colonoscopy

IMPORTANT PATHOLOGY CHARACTORISTICS Mitosis Ki67 Index Grade Criteria Low (G1) Intermediate (G2) <2 mitoses/10hpf + < 3% Ki67 index 2-20 mitoses/10hpf / 3-20% Ki67 index High (G3) >20 mitoses /10hpf/>20% Ki 67 index

CARCINOID SYNDROME When the primary tumour is in the GIT the serotonin and kallikrein are inactivated in the liver; manifestations of carcinoid syndrome do not occur until there are mets to the liver or cirrhosis. Carcinoid tumours arising in the bronchi may be associated with manifestations of carcinoid syndrome without liver metastases because their biologically active products reach the systemic circulation before passing through the liver and being metabolised.

THANK YOU

NANETS CONSENSUS GUIDELINES Tumour differentiation refers to the extent of resemblance to the normal cellular counterpart. Tumour grade refers to the degree of biologic aggressiveness and is related to differentiation but different. Tumour stage refers to the extent of spread of the tumour. Consensus from US,Europe,North America 2010 Grade Versus Differentiation in Neuroendocrine Tumors Differentiation Grade Well differentiated (WHO) Low grade (ENETS G1) Intermediate grade (ENETS G2) Poorly differentiated (WHO) High grade (ENETS G3) Lowell et al. Pancreas 2010 39:6;767-774

Grade Traditional ENETS / WHO Moran et al. Low Grade Carcinoid Tumour NET Grade 1 (G1) NEC Grade 1 Intermediate Grade Carcinoid Tumour NET Grade 2 (G2) NEC Grade 2 High Grade Small cell carcinoma NE carcinoma Grade 3 (G3) small cell carcinoma NEC Grade 3 small cell Large cell neuroendocrine carcinoma NE carcinoma Grade 3 (G3) large cell neuroendocrine NEC Grade 3 large cell

PROGNOSTIC FACTORS The general prognosis in carcinoid tumour is excellent compared with that of other visceral cancers. Based on a world literature of some 2,837 cases, the median 5- year survival rate for all cases is 82%